Richard B. Kim, MD, FRCPC, Division Chair
Dr. Kim received his medical degree from University of Saskatchewan, Canada in 1987. After completing an internship and residency training at Royal University hospital in Saskatoon Canada in 1991, he went on to carry out postdoctoral fellowship training in Clinical Pharmacology at Vanderbilt University.
In 1994, upon completion of his fellowship training, he remained at Vanderbilt Clinical Pharmacology as a faculty member until 2006. He is currently Professor and Chair of the Division of Clinical Pharmacology in the Department of Medicine at the University of Western Ontario in London, Canada. His research interest is that of understanding the molecular basis of interindividual differences in drug disposition and the application of such finding to the emerging field of Personalized Medicine.
Research areas under active investigation in his laboratory include that of drug transporters, CYP enzymes, and the pathways involved in the regulated expression of such proteins. He is a member of ASCPT, ISSX, and AAPS. He is an editor for the Medical Letter Handbook of Adverse Drug Interactions, and an associate editor for Molecular Pharmacology. He is a fellow of AAPS, and member of the American Society for Clinical Investigation (ASCI).

Publications
2005  2006  2007  2008  2009
<<<        >

Gradhand U., and Kim R.B.: Pharmacogenomics of MRP Transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev 40:317-54, 2008. [Pubmed]

Healan-Greeenberg C., Waring J.F., Kempf D., Blomme A.G., Tirona R.G., and Kim R.B.: A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Disp, 36:500-5007, 2008.  [Pubmed]

Krishnamurthy P., Schwab M., Takena K., Nachagari D., Morgan J., Leslie M., Du W., Boyd K., Cheok M., Nakauchi H., Marzolini C., Kim R.B., Poonkuzhali B., Schuetz E., Evans W., Relling M., and Schuetz J.D.: Transporter mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 68:4983-4989, 2008. [Pubmed]

Lee W., Lockhart A.C., Merchant N., Glaeser H., Harris E.I., Washington K., Zaika A., Kim R.B., and El-Rifai W.: Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 68:10315-10323, 2008. [Pubmed]

Meyer zu Schwabedissen H., Tirona R.G., Yip C.Y., Ho R.H., and Kim R.B.: Interplay between the nuclear receptor PXR and the uptake transporter OATP1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 68:4983-4989, 2008.  [Pubmed]

Schwarz U.I., Ritchie M.D., Bradford Y., Dudek S.M., Frye-Anderson A., Kim R.B., Roden D.M., and Stein C.M.: VKORC1 variants determine warfarin requirements during initiation of anticoagulation. New Engl. J. Med 358:999-1008, 2008. [Pubmed]

Urquhart B.L., Ware J.A., Tirona R.G., Ho R.H., Leake B.F., Schwarz U.I., Zaher H., Palandra J., Gregor J.C., Dresser G.K., and Kim R.B.: BCRP (ABCG2) and drug disposition: Intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet. Genomics 18:439-448, 2008. [Pubmed]

Zaher H., Meyer zu Schwabedissen H., Tirona, R.G., Cox M., Obert L., Agrawal N., Palandra J., Stock J.L., Kim R.B., and Ware J.A.; Targeted disruption of murine organic anion-transporting polypeptide 1b2 (oatp1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74:320-329, 2008. [Pubmed]